Executive Summary

Medical affairs is becoming increasingly data-intensive, globally connected, and strategically important to pharmaceutical organizations. Medical teams must interpret rapidly expanding scientific literature, respond to increasingly complex healthcare professional (HCP) questions, support evidence generation, coordinate field medical activities, and communicate emerging scientific insights across the organization.

Generative artificial intelligence (GenAI) is beginning to reshape how these activities are performed.

Unlike traditional automation, GenAI can generate, summarize, classify, and transform complex scientific information into usable outputs. This creates opportunities to reduce administrative workloads, accelerate information retrieval, personalize scientific engagement, and improve how medical teams interact with internal and external stakeholders.

The opportunity is significant, but so are the responsibilities. Medical affairs operate in an environment where scientific accuracy, medical integrity, data privacy, regulatory compliance, and human accountability are essential. GenAI therefore cannot simply be deployed as a productivity tool without appropriate governance and expert oversight.

The future of medical affairs will likely involve a hybrid operating model in which AI handles high-volume information and content workflows while medical professionals remain responsible for interpretation, scientific judgment, and stakeholder relationships.

Key Themes

• GenAI is automating high-volume medical affairs information workflows
• Scientific content creation and summarization are becoming faster
• AI can improve the productivity of medical science liaison (MSL) teams
• Medical information and literature monitoring are becoming increasingly intelligent
• Strong governance and human oversight remain essential for responsible adoption

1. Scientific Content Creation and Adaptation

One of the most immediate applications of GenAI in medical affairs is the creation and adaptation of scientific content.

Medical teams produce large volumes of materials for internal stakeholders, HCPs, congresses, advisory boards, training programs, and scientific communications. GenAI can help draft, summarize, restructure, and adapt approved scientific information for different audiences and formats.

Applications include:

• Scientific summaries
• HCP educational materials
• Internal medical briefings
• Congress preparation
• Medical training content

The primary value is not replacing medical writers or experts. It is reducing repetitive drafting work so professionals can spend more time on scientific review and strategic activities.

2. Medical Literature Monitoring and Summarization

Medical affairs teams must continuously monitor an expanding global body of scientific literature.

GenAI can help process large volumes of publications, identify relevant information, summarize findings, and organize evidence around specific therapeutic areas or scientific questions.

Potential applications include:

• Literature summarization
• Emerging evidence identification
• Competitive intelligence
• Publication monitoring
• Scientific trend analysis

This can significantly reduce the time required to identify relevant information while helping medical teams maintain broader visibility across rapidly evolving research landscapes.

Human review remains critical, particularly when generated summaries influence scientific or medical decisions.

3. Intelligent Medical Information Support

Medical information teams handle large numbers of questions from HCPs and other stakeholders.

GenAI can help retrieve relevant information from approved internal knowledge repositories and generate draft responses based on established scientific and medical content.

Capabilities may include:

• Question classification
• Information retrieval
• Response drafting
• Reference identification
• Content summarization

This can reduce response times while allowing medical information professionals to focus on complex questions requiring deeper scientific judgment.

The greatest value comes from connecting GenAI to controlled, authoritative sources rather than allowing unrestricted generation of medical information.

4. AI Support for Medical Science Liaisons

MSLs spend significant time preparing for scientific discussions, reviewing literature, documenting interactions, and identifying relevant insights.

GenAI can act as a productivity assistant across these workflows.

Potential applications include:

• HCP preparation briefs
• Scientific literature summaries
• Meeting preparation
• Interaction documentation
• Follow-up material drafting
• Territory-level scientific insights

This enables MSLs to spend more time on high-value scientific engagement rather than administrative preparation.

The role of the MSL is therefore likely to evolve rather than disappear, with AI serving as an intelligence layer supporting human scientific relationships.

5. Advisory Board and Expert Engagement Support

Advisory boards generate valuable scientific insights, but organizing, analyzing, and synthesizing these discussions can be resource-intensive.

GenAI can help medical affairs teams prepare questions, organize discussion themes, summarize meeting outputs, and identify recurring scientific perspectives.

Applications include:

• Agenda preparation
• Expert background summaries
• Discussion synthesis
• Theme identification
• Post-meeting reporting

When properly governed, GenAI can help medical teams extract greater strategic value from expert interactions while reducing administrative workloads.

6. Evidence Synthesis and Scientific Intelligence

Medical affairs teams increasingly need to integrate evidence from clinical trials, publications, real-world data, registries, and other sources.

GenAI can help organize complex evidence landscapes and generate structured summaries that support scientific interpretation.

Organizations can use GenAI to assist with:

• Evidence mapping
• Scientific landscape reviews
• Trial comparisons
• Therapeutic-area summaries
• Competitive intelligence

This is particularly valuable in rapidly evolving therapeutic areas where new evidence can emerge faster than teams can manually review it.

GenAI does not eliminate the need for evidence appraisal. Instead, it can accelerate the process of finding and organizing information for expert evaluation.

7. Congress and Scientific Event Intelligence

Medical affairs teams monitor major scientific congresses to understand emerging research, competitor developments, clinical data, and changes in treatment paradigms.

GenAI can help transform large volumes of congress information into structured intelligence.

Applications include:

• Presentation summarization
• Poster analysis
• Abstract classification
• Competitive intelligence
• Emerging trend identification

Instead of relying solely on manual review after an event, organizations can build more systematic processes for capturing and distributing relevant scientific intelligence across medical teams.

8. Medical Strategy and Insight Generation

GenAI can increasingly support the synthesis of insights generated across medical affairs activities.

Information from MSL interactions, advisory boards, literature, congresses, medical information inquiries, and real-world evidence can be analyzed to identify recurring themes and emerging scientific questions.

This may help medical leaders understand:

• Unmet evidence needs
• Recurring HCP questions
• Emerging treatment concerns
• Evidence gaps
• Scientific trends

The strategic opportunity is significant because medical affairs can move from collecting fragmented insights toward building a more continuous scientific intelligence capability.

9. Personalized HCP Scientific Engagement

GenAI can help medical teams personalize scientific content based on the needs and interests of individual HCP audiences.

Instead of delivering identical information to every stakeholder, organizations can potentially tailor content around therapeutic expertise, scientific interests, previous interactions, and information needs.

Applications include:

• Personalized scientific summaries
• Relevant literature recommendations
• Customized educational materials
• HCP-specific information packages

Personalization must remain grounded in approved scientific information and appropriate medical governance. The objective should be greater relevance, not uncontrolled automated communication.

10. Medical Affairs Knowledge Management

Pharmaceutical organizations possess enormous amounts of scientific knowledge distributed across documents, databases, publications, presentations, research programs, and internal systems.

GenAI can make these knowledge assets easier to access and use.

Enterprise knowledge systems can help medical teams:

• Search complex scientific information
• Summarize internal documents
• Connect related evidence
• Retrieve approved content
• Accelerate knowledge sharing

This could transform medical affairs knowledge management from static document repositories into intelligent scientific knowledge ecosystems.

Strategic Implications for Pharma Leaders

Generative AI is likely to become an important productivity layer across medical affairs, but successful adoption will depend on how effectively organizations combine technology with scientific governance.

The greatest opportunity is not simply automating individual tasks. It is redesigning medical affairs workflows around faster access to trusted information, continuous insight generation, and more productive human interactions.

Several strategic priorities are emerging:

• Build governed enterprise GenAI environments for medical teams
• Connect AI systems to authoritative scientific and medical knowledge sources
• Establish clear human-review and accountability models
• Train medical professionals to use GenAI effectively
• Protect confidential, patient, and proprietary information
• Measure AI adoption through productivity and quality outcomes

Regulatory expectations are also becoming increasingly relevant. FDA has highlighted the expanding use of AI and generative AI across the drug product lifecycle and has emphasized risk-based approaches, trustworthy use, and appropriate oversight. FDA and EMA’s January 2026 joint principles further reinforce the importance of context of use, data governance, performance, transparency, and lifecycle management for AI in drug development. (U.S. Food and Drug Administration)

For medical affairs leaders, governance should therefore be designed alongside GenAI adoption rather than added after deployment.

The Future of Generative AI in Medical Affairs

The next phase of GenAI adoption will likely move beyond isolated productivity applications toward integrated medical intelligence platforms.

Emerging capabilities include:

• AI copilots for MSLs and medical information teams
• Agentic AI coordinating medical affairs workflows
• Enterprise scientific knowledge assistants
• Continuous evidence monitoring
• AI-generated scientific intelligence dashboards
• Personalized medical education platforms

The longer-term opportunity is to create a continuously learning medical affairs ecosystem in which scientific information is captured, analyzed, synthesized, and distributed across the organization with far greater speed.

However, medical expertise will remain central. GenAI can accelerate information processing, but scientific interpretation, clinical judgment, ethical decisions, and trusted HCP relationships will continue to require human leadership.

Key Takeaways

• GenAI is accelerating scientific content creation and adaptation
• Literature monitoring and evidence synthesis are becoming more efficient
• Medical information teams can use AI to accelerate information retrieval and response drafting
• MSLs can use GenAI to improve preparation and reduce administrative workloads
• Advisory board and congress intelligence can be analyzed more efficiently
• AI can help identify scientific insights across fragmented medical data
• Personalized scientific engagement is becoming more achievable
• Enterprise knowledge management is evolving toward intelligent scientific ecosystems
• Governance and human oversight remain essential
• The future of medical affairs will combine AI productivity with human scientific expertise

Conclusion

Generative AI is beginning to transform medical affairs from an information-intensive function into a more intelligent, connected, and insight-driven organization.

Its applications extend from scientific content creation and literature monitoring to medical information, MSL productivity, evidence synthesis, congress intelligence, HCP engagement, and enterprise knowledge management. These capabilities can reduce administrative workloads while giving medical professionals faster access to the information they need to make informed decisions.

Yet the strategic value of GenAI will depend on more than model performance. Pharmaceutical companies will need trusted data, strong governance, secure infrastructure, clear accountability, and medical professionals capable of evaluating AI-generated outputs.

The organizations that lead the next generation of medical affairs will likely be those that treat GenAI not simply as a productivity tool, but as an intelligence capability embedded across the medical operating model. As scientific information continues to expand at unprecedented speed, the ability to turn that information into trusted, actionable medical insight may become one of the most important competitive capabilities in pharmaceutical organizations.

Medical Affairs and the Rise of Generative AI

Medical Affairs is increasingly adopting generative AI to improve productivity, accelerate scientific workflows, and support better access to medical information. As pharmaceutical organizations generate larger volumes of scientific data, Medical Affairs teams can use AI tools to organize information and assist with repetitive knowledge-intensive tasks.

1. Medical Affairs Scientific Content Creation

Generative AI can help Medical Affairs teams draft scientific summaries, briefing documents, educational materials, and internal communications. Human medical and scientific review remains essential to ensure accuracy, appropriate context, and compliance.

2. Medical Affairs Literature Analysis

AI can help Medical Affairs professionals search, summarize, and organize large volumes of scientific literature. This can make literature monitoring more efficient and help Medical Affairs teams identify relevant publications and emerging scientific themes.